Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and relaxing, despite the drumbeat of gloomy dispatches from around the globe. Nonetheless, the world, such as it is, keeps spinning. So time to give it an extra nudge with a delicious cup of stimulation. Our choice today — for those who track this sort of thing — is ginger spice. Feel free to join us. Meanwhile, here are some tidbits to help you get started. We hope your day is productive and manageable. And so stay safe — wear a mask….

Biogen (BIIB) reduced the price of its Alzheimer’s drug Aduhelm by half and is planning a series of cost-cutting measures across the company next year that aim to save $500 million, STAT reports. The moves follow a disappointing commercial launch, as well as anger over the high price. The new, lower price is $28,200, or roughly half what the drug cost when it launched in June. Insurance companies balked at its original list price, averaging $56,000 a year per patient, while physicians have fervently questioned whether Biogen’s supporting evidence merited approval by the U.S. Food and Drug Administration, let alone widespread use.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment